Protagonist Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Protagonist Therapeutics

06/08/2025 22:12

Protagonist Therapeutics Inc PTGX.OQ reported a quarterly adjusted loss of 55 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -50 cents.  The mean expectation of twelve analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -76 cents to -24 cents per share.

Revenue rose 33.1% to $5.55 million from a year ago; analysts expected $6.81 million.

Protagonist Therapeutics Inc's reported EPS for the quarter was a loss of 55 cents​.

The company reported a quarterly loss of $34.77 million.

Protagonist Therapeutics Inc shares had fallen by 2.5% this quarter and gained 39.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 0.9% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $70.00, about 23% above its last closing price of $53.90

This summary was machine generated from LSEG data August 6 at 09:12 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.58
-0.55
Beat
Mar. 31 2025
-0.23
-0.19
Beat
Dec. 31 2024
0.32
1.98
Beat
Sep. 30 2024
-0.61
-0.54
Beat